Abstract
Novel chitosan-carrageenan nanoparticles were produced through the process of ionotropic gelation for the encapsulation and controlled release of recombinant human erythropoietin (rHu-EPO). The effects of chitosan concentration, chitosan to carrageenan mass ratio and solution pH on the nanoparticle diameter, polydispersity and surface charge were explored through both screening and response surface modeling (RSM) methods. The chitosan-carrageenan nanoparticles created had particle diameters between 200 and 1000nm, surfaces charges between 40 and 55mV, and polydispersity between 0.2 and 0.35. RSM optimized chitosan-carrageenan nanoparticles demonstrated an increased rHu-EPO encapsulation efficiency of 47.97±4.10% and a more sustained in vitro release of ~50% over a 2 week period when compared to previous nano/microparticle delivery systems. Studies on the effect of surface charge and chitosan molecular weight on the encapsulation and controlled release of rHu-EPO revealed that increasing either led to improved encapsulation efficiency and reduced release rate.
Keywords: Chitosan, Carrageenan, Drug delivery, Erythropoietin, Nanoparticles, Response surface modeling, cellular membranes, inflammatory pathological condition.
Current Drug Delivery
Title:Encapsulation and Controlled Release of Recombinant Human Erythropoietin from Chitosan-Carrageenan Nanoparticles
Volume: 9 Issue: 5
Author(s): Cody Bulmer, Argyrios Margaritis and Anargyros Xenocostas
Affiliation:
Keywords: Chitosan, Carrageenan, Drug delivery, Erythropoietin, Nanoparticles, Response surface modeling, cellular membranes, inflammatory pathological condition.
Abstract: Novel chitosan-carrageenan nanoparticles were produced through the process of ionotropic gelation for the encapsulation and controlled release of recombinant human erythropoietin (rHu-EPO). The effects of chitosan concentration, chitosan to carrageenan mass ratio and solution pH on the nanoparticle diameter, polydispersity and surface charge were explored through both screening and response surface modeling (RSM) methods. The chitosan-carrageenan nanoparticles created had particle diameters between 200 and 1000nm, surfaces charges between 40 and 55mV, and polydispersity between 0.2 and 0.35. RSM optimized chitosan-carrageenan nanoparticles demonstrated an increased rHu-EPO encapsulation efficiency of 47.97±4.10% and a more sustained in vitro release of ~50% over a 2 week period when compared to previous nano/microparticle delivery systems. Studies on the effect of surface charge and chitosan molecular weight on the encapsulation and controlled release of rHu-EPO revealed that increasing either led to improved encapsulation efficiency and reduced release rate.
Export Options
About this article
Cite this article as:
Bulmer Cody, Margaritis Argyrios and Xenocostas Anargyros, Encapsulation and Controlled Release of Recombinant Human Erythropoietin from Chitosan-Carrageenan Nanoparticles, Current Drug Delivery 2012; 9 (5) . https://dx.doi.org/10.2174/156720112802650680
DOI https://dx.doi.org/10.2174/156720112802650680 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Low Molecular Weight Compounds with Transition Metals as Free Radical Scavengers and Novel Therapeutic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Stressing Conditions as Tools to Boost the Biosynthesis of Valuable Plant Natural Products
Recent Patents on Biotechnology Therapeutic Potential of Stem/Progenitor Cells in Human Skeletal Muscle for Cardiovascular Regeneration
Current Stem Cell Research & Therapy Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design Protective Effect of Heat Shock Proteins in the Nervous System
Current Neurovascular Research Off-Pump Coronary Artery Bypass Grafting; is it Still Relevant?
Current Cardiology Reviews Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Adeno-associated Virus 9-mediated Small RNA Interference of TLR4 Alleviates Myocardial Ischemia and Reperfusion Injury by Inhibition of the NF-κB and MAPK Signaling Pathways in Rats
Current Molecular Medicine Ozone: A Multifaceted Molecule with Unexpected Therapeutic Activity
Current Medicinal Chemistry Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors
Recent Patents on Nanotechnology Heart Rate Lowering by Inhibition of the Pacemaker Current: A New Therapeutic Perspective in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry